Dr. Wassman is Chief Medical Officer and Executive Vice President, Clinical Development for MARA Biosciences. A specialist in personalized medicine, laboratory medicine, and genetic diagnostics, he has pioneered translation and delivery of cutting-edge diagnostic technology to clinical service in the areas of reproductive medicine, cancer, neurodevelopmental disabilities, and companion diagnostics, for over 40-years. He co-founded several successful ventures and consulted for a wide variety of entities. Previously he served as Chief Medical Officer for Genzyme Genetics, Lineagen, Rosetta Genomics, Generation Health (CVS), Helicos Biosciences, Good Start Genetics, Celula, Ambry Genetics, Alfigen, and was Co-Director of Predictive Laboratories. Currently he also serves as a Board Director for TESS Research Foundation, a non-profit focused on treatments for epilepsy due to deficiency of SLC13A5. He is a graduate of Yale University and Albany Medical College and Board Certified in Pediatrics and Medical Genetics. He has formal training and both public and private sector experience in reimbursement, and international experience.